← Back to Clinical Trials
Recruiting NCT04272515
Molecular Characterization for Understanding Biliary Atresia
◆ AI Clinical Summary
Plain-language summary for patients
Trial Parameters
Condition Biliary Atresia
Sponsor Institut National de la Santé Et de la Recherche Médicale, France
Study Type INTERVENTIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2021-02-07
Completion 2026-02-07
Interventions
blood samplingskin biopsy samplingexplanted liver of BA patients sampling
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Although considered a rare disease, Biliary Atresia (BA) is the leading cause of neonatal cholestasis and liver transplantation in children. Little is known about the molecular mechanisms that drive BA. The purpose of this study is to collect the fluid samples, explanted liver tissue samples and dermal biopsy samples to enable investigators to perform the genetic and molecular analyses that might point to the gene(s) and cellular pathway involved in etiology of BA disease.
Eligibility Criteria
Inclusion Criteria: * confirmed diagnosis of biliary atresia in patients * parents of BA patients Exclusion Criteria: * no
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology